Skip to main content

EA2176 A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

NCT04444921

A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

Associated Conditions

Anal Cancer

Principal Investigator

Sponsor

Eastern Cooperative Oncology Group

This study is being done to answer the following question: Will adding an immune checkpoint inhibitor to the usual combination of chemotherapy drugs help prevent your cancer from getting worse? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your anal canal cancer The usual approach is defined as care most people get from metastatic anal cancer. These treatments may reduce symptoms and may stop the tumor from growing for a few months or longer.

This study is currently enrolling.